By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288


SEARCH JOBS
AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.


Key Statistics


Email: n/a
Ownership: Public

Web Site: AmpliPhi Bio
Employees:
Symbol: APHB
 





Collaborations

Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.





Company News
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase I Trial Of AB-SA01 12/5/2016 11:24:52 AM
AmpliPhi Bio (APHB) Announces Pricing Of Public Offering Of Common Stock And Warrants 11/17/2016 8:02:25 AM
AmpliPhi Bio (APHB) Announces Settlement Of Pending Lawsuit 11/14/2016 11:03:48 AM
AmpliPhi Bio (APHB) Reports Third Quarter 2016 Financial Results And Provides Corporate Update 11/11/2016 9:29:48 AM
AmpliPhi Bio (APHB) Granted Small And Medium Enterprise Status By EMA 11/1/2016 11:45:25 AM
AmpliPhi Bio (APHB) Announces Favorable Topline Safety And Tolerability Results From Its Phase I Trial In Patients With Chronic Rhinosinusitis 10/25/2016 10:49:57 AM
AmpliPhi Bio (APHB) Appoints Dr. Carrie-Lynn Langlais Furr As Vice President Of Regulatory Affairs And Program Management 10/17/2016 11:45:19 AM
AmpliPhi Bio (APHB) Appoints Dr. Carrie-Lynn Langlais Furr As Vice President of Regulatory Affairs And Program Management 10/17/2016 7:27:40 AM
AmpliPhi Bio (APHB) Provides Update On Phase I Trial In Chronic Rhinosinusitis Patients 9/20/2016 11:04:05 AM
AmpliPhi Bio (APHB) To Participate In Upcoming Conferences 9/13/2016 12:15:03 PM
12345678910...
//-->